Use of (4-Alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease
申请人:Lecanu Laurent
公开号:US20090197891A1
公开(公告)日:2009-08-06
The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.
The invention provides a therapeutic method for treating at least one symptom of Alzheimer’s disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal in need of such therapy, an effective amount of a benzoylpiperazine derivative, including pharmaceutically acceptable salts thereof.
Unique spirocyclopiperazinium salt I: synthesis and structure–Activity relationship of spirocyclopiperazinium salts as analgesics
作者:Feng-Li Gao、Xin Wang、Hong-Mei Zhang、Tie-Ming Cheng、Run-Tao Li
DOI:10.1016/s0960-894x(03)00177-x
日期:2003.5
spirocyclopiperazinium derivatives 7a-n and 10a-h were synthesized and evaluated for their in vivo analgesic and sedative activities. Compounds 7f and 10c were discovered to exhibit excellent analgesic activity. Structure-activityrelationships revealed that anion of the quaternary salt affected the analgesic and sedative activity significantly; the allyl group is a most effective group among the compounds